english.prescrire.org > Prescrire International > N°236 - April 2022

n°236

April 2022

Issue Contents
Editorial

Free  Balancing act

p.87

Marketing Authorisations


Selpercatinib (Retsevmo°) in certain types of lung or thyroid cancer

p.89-90

Ofatumumab (Kesimpta°) in multiple sclerosis

p.90-91

Cefiderocol (Fetcroja°) in aerobic Gram-negative bacterial infections

p.91

Free  Dupilumab (Dupixent°) in severe atopic eczema from 6 years of age

p.92

Editors' opinion. Negligence

p.93

Amikacin (Arikayce liposomal°) by oral inhalation for some mycobacterial lung infections

p.93

Cabotegravir (Vocabria°) and rilpivirine (Rekambys°) IM injections in HIV infection

p.94-95
An alternative to oral two-drug regimens

Acalabrutinib (Calquence°) in chronic lymphocytic leukaemia

p.95

Upadacitinib (Rinvoq°) in psoriatic arthritis

p.96

Indacaterol + mometasone (Atectura Breezhaler°) in persistent asthma

p.96

Tozinameran (Comirnaty°) and covid-19 in adolescents

p.97

Elasomeran (Spikevax°) and covid-19 in adolescents

p.97

Tozinameran (Comirnaty°) and covid-19 in children aged 5-11 years

p.97

Colchicine in covid-19 warranting hospitalisation: not worth the risk

p.97

Olaparib (Lynparza°) in metastatic prostate cancer with BRCA mutation, after failure of abiraterone or enzalutamide

p.98-99

Lanthanum in patients undergoing dialysis

p.99
No more effective than calcium carbonate and possibly more cardio­vascular deaths

Free  Prescrire's ratings of new drugs in 2021: a brief review

p.100-102

Adverse Effects


Isotretinoin: developmental neuropsychiatric disorders, without visible malformations at birth

p.103-104

Triptans during pregnancy: more safety signals (continued)

p.105

Fast-acting fentanyl: overdose and dependence

p.106

Ceftriaxone: seizures, hallucinations, mental confusion

p.106

Common stem: -gest, -gest-, gest-

p.107

Commen stem: -terol

p.107

Outlook


The Innovative Medicines Initiative: a European public-private partnership that mostly benefits Big Pharma

p.108-111

The pharmaceutical company Aspen: European sanction for abuse of dominant market position

p.111

Masthead


Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe